Spiderwort is a biotechnology company using tissue engineering to create biomaterials for repairing and regenerating the human body that is headquartered in Ottawa, Ontario and was founded in 2015 by Andrew Pelling and Charles M. Cuerrier. The company is using plant derived cellulose to create biomaterial scaffolding architectures that are biocompatible and capable of inducing angiogenesis (blood vessel generation), promote cell infiltration, promote cell growth, promote tissue repair, and promote tissue reconstruction.
On June 10, 2019 Spiderwort announced raising CA$500,000 from the CEO of Assent Compliance Andrew Waitman. At the time of announcing their angel funding round the company also announced Dane Bedward, an executive fellow with Mistral Ventures Partners, and Peter Morand, former CEO and president of Natural Sciences and Engineering Research Council of Canada and the founding CEO of the Canadian Science and Technology Growth Fund, will be joining the company's board of directors.
On May 27, 2020 Spiderwort announced raising $2.5 million in seed funding from Horizons Ventures (lead investors), Capital Angel Network, Break Off Capital, and Anges Quebec. The company plans on using their seed funding to develop a treatment for spinal cord injuries using plant-based materials. Spiderwort also named Dane Benward, the former president of Genzyme Canada and executive fellow of Mistral Venture Partners, the chairman of Spiderworts board of directors. Patrick Zhang from Horizons Ventures also joined the board of Spiderwort at the time of seed funding.
Timeline
On May 27, 2020 Spiderwort announced raising $2.5 million in seed funding from Horizons Ventures (lead investors), Capital Angel Network, Break Off Capital, and Anges Quebec.
On June 10, 2019 Spiderwort announced raising CA$500,000 from the CEO of Assent Compliance Andrew Waitman.
